FDA

Ecosystem Capabilities for Total Product Lifecycle Oversight of AI/ML Medical Devices

The need for Independent Testing Infrastructure for FDA-Guideline-Compliant Validation

By: Miguel Amador, Chief Innova ion Officer

Data: 11/6/2025

TPLC Operational Requirements - What's Needed?

COMPLEAR
HEALTH

Operationalizing Total Product Lifecycle for AI/ML medical devices necessitates distributed ecosystem capabilities due to the limitations of the traditional bilateral model.

Pre-market Validation

Test algorithms across diverse populations and settings requires representative datasets, technical infrastructure for bias assessment, and clinical expertise for performance interpretation.

Market Authorization

Evidence-based decision-making requires standardized evaluation protocols, independent validation, and transparent documentation of algorithm behavior.

Post-market Monitoring

Continuous assessment of real-world performance at scale requires systematic access to clinical deployment data, automated detection of performance drift or bias, and rapid identification of safety signals.

Adaptive Oversight

Assess whether algorithm modifications improve performance, validate changes before deployment, and ensure predetermined change control protocols are followed.

TPLC requires systematic testing capacity throughout the lifecycle—from pre-market validation through continuous post-market monitoring and update validation.

Current FDA-Manufacturer Bilateral Model's Limitations

COMPLEAR HEALTH

TPLC operational execution requires ecosystem capabilities beyond the bilateral FDA-manufacturer relationship.

The Bilateral Model Structure

Two-party relationship: FDA reviews submissions from individual manufacturers in arms-length regulatory relationship

Manufacturer generates validation evidence, conducts post-market surveillance, and submits documentation to FDA

FDA reviews documentation, makes authorization decisions, and enforces compliance with regulatory requirements

This bilateral structure works effectively for static medical devices when manufacturers have the resources to independently establish comprehensive validation and monitoring capabilities. The model assumes that once a device is validated and approved, its performance characteristics remain constant.

For TPLC oversight of AI/ML devices that continuously learn and adapt, this bilateral structure reveals several operational gaps that cannot be addressed through the two-party relationship alone.

Why Bilateral Oversight
Cannot Provide Complete TPLC Capacity?

COMPLEAR
HEALTH

Manufacturers lack access to diverse validation datasets across different clinical settings and patient populations

FDA lacks capacity for continuous monitoring across all AI device deployments

No shared infrastructure for standardized testing protocols accessible to all developers

Competency trap: Only large manufacturers can afford independent validation capabilities, creating market barriers

TPLC operational execution requires ecosystem capabilities beyond the bilateral FDA-manufacturer relationship.

TPLC Operational Requirements - Toolbox

COMPLEAR HEALTH™

The EU has operationalized several ecosystem components that map directly to TPLC operational requirements. Each component addresses a specific gap in the bilateral model. These are puzzle pieces, not a complete solution—but each provides a functional capability that TPLC demands.

TPLC Need	EU Component	Function Provided
Pre-market Validation	AI Regulatory Sandboxes	Controlled testing environments with real-world data and regulatory oversight
Robust Testing Infrastructure	TEF-Health Facilities	Shared validation capabilities accessible to all developers
Real-world Data Access	EHDS (European Health Data Space)	Federated data infrastructure for pre-market and post-market needs
Value-based Oversight	HTA Integration	Performance-to-value assessment linking regulation to clinical utility

Each component addresses a specific TPLC operational gap that bilateral oversight cannot fill.

Regulatory Sandboxes
Enable Pre-Market Evidence Generation

Controlled real-world testing environment with regulatory oversight

Access to diverse patient populations and clinical settings

Early visibility into algorithm performance and failure modes

Documentation of evidence for regulatory submissions

EU Example

EU AI Sandboxes created in each country by 2026, relies on national regulators and data testing facilities for real world pilots.

UK Example

The UK's MHRA AI Airlock is a sandbox model provides a structured, collaborative framework that de-risks innovation by enabling supervised, real-world testing.

Sandboxes could provide FDA-guideline-compliant evidence generation in real-world settings.

Testing Facilities
Provide Standardized Validation Infrastructure

Shared infrastructure for rigorous validation using standardized protocols

Independent assessment capabilities accessible to all developers

Specialized expertise in AI validation methodologies

Consistent validation quality regardless of manufacturer resources

Example: EU TEF-Health Network

Provides standardized testing protocols for bias assessment, robustness evaluation, and clinical safety validation that align with regulatory requirements

Testing facilities democratize access to FDA-guideline-compliant validation infrastructure, enabling all developers to meet rigorous standards regardless of organizational resources.

Shared Data Spaces Infrastructure Enables Post-Market Monitoring

(a) Workflow of centralized learning

(b) Workflow of federated learning

Federated access to real-world health data across deployment sites

Systematic performance monitoring in operational settings

Drift detection identifying performance degradation

Evidence generation for algorithm updates and modifications

EU Example: EHDS

European Health Data Space federated network will enable continuous monitoring of AI device performance across healthcare systems while maintaining data privacy.

Data infrastructure makes continuous TPLC monitoring operationally feasible.

HTA Integration Links Approval to Patient Benefit

Joint integration of FDA and Centers for Medicare & Medicaid Services (CMS) reviews

Add clinical outcomes assessment beyond technical metrics to evaluate real-world patient benefit

Enable real-world evidence of patient benefit in operational healthcare settings

Include cost-effectiveness evaluation assessing whether clinical benefits justify healthcare system costs

Continuous value reassessment as real-world evidence accumulates post-market

HTA ensures regulatory approval translates to meaningful patient benefit, not just technical compliance.

Integrated Components Enable Complete TPLC

These components work together as an integrated system, not isolated tools:

Sandboxes generate evidence through controlled real-world testing, producing the performance data and failure mode documentation that TPLC requires

Testing facilities validate rigorously using standardized protocols, ensuring consistent validation quality accessible to all developers

Shared Data infrastructure enables monitoring through federated data access, making continuous post-market surveillance operationally feasible

HTA assesses value by linking regulatory approval to real-world patient benefit and cost-effectiveness

Each component addresses a specific TPLC operational gap. Together they create distributed capacity for complete lifecycle oversight—from pre-market evidence generation through rigorous validation, continuous post-market monitoring, and ongoing value assessment. Independent testing infrastructure makes TPLC operationally achievable.

TPLC requires integrated ecosystem capabilities, not isolated components. Independent testing infrastructure enables the systematic validation and monitoring that FDA guidelines demand throughout the product lifecycle.

Miguel Amador
miguel.amador@complear.com

Digital Health Compliance Made Easy and Clear from Day 1